Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort.

Autor: Ezponda A; Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain., Casanova C; Pulmonary Department, Hospital Ntra Sra de Candelaria, Tenerife, Spain.; Respiratory Research Unit, Hospital Ntra Sra de Candelaria, Tenerife, Spain., Divo M; Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Marín-Oto M; Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain., Cabrera C; Pulmonary Department, Hospital Universitario Doctor Negrín, Las Palmas, Spain., Marín JM; Pulmonary Department, Hospital Universitario Miguel Servet, Instituto Aragonés Ciencias Salud & CIBERES, Zaragoza, Spain., Bastarrika G; Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain., Pinto-Plata V; Pulmonary Department, Baystate Medical Center, Springfield, Massachusetts, USA., Martin-Palmero Á; Respiratory Investigation Unit, Queen's University, Kingston, Ontario, Canada., Polverino F; Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona, USA., Celli BR; Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., de Torres JP; Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain.; Respiratory Investigation Unit, Queen's University, Kingston, Ontario, Canada.; Respirology and Sleep Medicine Division, Queen's University, Kingston, Ontario, Canada.
Jazyk: angličtina
Zdroj: Respirology (Carlton, Vic.) [Respirology] 2022 Apr; Vol. 27 (4), pp. 286-293. Date of Electronic Publication: 2022 Feb 07.
DOI: 10.1111/resp.14223
Abstrakt: Background and Objective: The availability of chest computed tomography (CT) imaging can help diagnose comorbidities associated with chronic obstructive pulmonary disease (COPD). Their systematic identification and relationship with all-cause mortality have not been explored. Furthermore, whether their CT-detected prevalence differs from clinical diagnosis is unknown.
Methods: The prevalence of 10 CT-assessed comorbidities was retrospectively determined at baseline in 379 patients (71% men) with mild to severe COPD attending pulmonary clinics. Anthropometrics, smoking history, dyspnoea, lung function, exercise capacity, BODE (BMI, Obstruction, Dyspnoea and Exercise capacity) index and exacerbations rate were recorded. The prevalence of CT-determined comorbidities was compared with that recorded clinically. Over a median of 78 months of observation, the independent association with all-cause mortality was analysed. A 'CT-comorbidome' graphically expressed the strength of their association with mortality risk.
Results: Coronary artery calcification, emphysema and bronchiectasis were the most prevalent comorbidities (79.8%, 62.7% and 33.9%, respectively). All were underdiagnosed before CT. Coronary artery calcium (hazard ratio [HR] 2.09; 95% CI 1.03-4.26, p = 0.042), bronchiectasis (HR 2.12; 95% CI 1.05-4.26, p = 0.036) and low psoas muscle density (HR 2.61; 95% CI 1.23-5.57, p = 0.010) were independently associated with all-cause mortality and helped define the 'CT-comorbidome'.
Conclusion: This study of COPD patients shows that systematic detection of 10 CT-diagnosed comorbidities, most of which were not detected clinically, provides information of potential use to patients and clinicians caring for them.
(© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
Databáze: MEDLINE
Externí odkaz: